本文關(guān)鍵詞：外周血單個(gè)核細(xì)胞的長(zhǎng)期體外培養(yǎng)及丙型肝炎病毒細(xì)胞模型的建立　出處：《山東大學(xué)》2005年博士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： 基因 端粒酶 逆轉(zhuǎn)錄酶 肝炎病毒 丙型 淋巴細(xì)胞

【摘要】：背景 丙型肝炎病毒(hepatitis C virus,HCV)是輸血后非甲非乙型肝炎的主要病因,而丙型肝炎也是一種全球性的傳染性肝病。急性丙型肝炎患者中,有超過(guò)50-85%的患者將發(fā)展成為慢性丙型肝炎,如果病情進(jìn)一步進(jìn)展還將發(fā)展為肝硬化和肝細(xì)胞肝癌。據(jù)美國(guó)疾病預(yù)防與控制中心統(tǒng)計(jì),約20%至30%的慢性丙型肝炎患者最終將出現(xiàn)致命的臨床癥狀和并發(fā)癥。據(jù)專家預(yù)測(cè),在今后的10-20年內(nèi),由于目前無(wú)癥狀或輕癥患者將發(fā)展成為終末期肝病甚至肝癌,慢性丙型肝炎將成為醫(yī)療衛(wèi)生保障系統(tǒng)的主要負(fù)擔(dān)之一。1989年,人們首次應(yīng)用分子生物學(xué)技術(shù)識(shí)別了丙型肝炎病毒基因組。但是,到目前為止,仍然沒(méi)有建立理想的丙型肝炎病毒細(xì)胞模型。雖然,人們對(duì)丙型肝炎病毒基因結(jié)構(gòu)和單獨(dú)病毒蛋白的認(rèn)識(shí)不斷增加,但是由于缺乏這種可靠和有效的病毒培養(yǎng)系統(tǒng),丙型肝炎病毒復(fù)制和致病機(jī)制的研究均受到了很大限制。同時(shí),關(guān)于丙型肝炎疫苗和有效治療方法的研究也無(wú)法進(jìn)行。丙型肝炎病毒能夠感染淋巴細(xì)胞源性細(xì)胞,特別是人外周血單個(gè)核細(xì)胞(human peripheral blood mononuclear cells,PBMC)。但是,PBMC屬于正常的體細(xì)胞,其生存期有限,不能夠用于長(zhǎng)期的觀察和研究。如果用正常PBMC來(lái)建立體外長(zhǎng)期培養(yǎng)的丙型肝炎病毒細(xì)胞模型,就必須延長(zhǎng)PBMC的生存期。 真核細(xì)胞的染色體決定了該細(xì)胞的基因型,染色體的末端結(jié)構(gòu)被稱為端粒。胚胎細(xì)胞具有較長(zhǎng)的染色體,而衰老細(xì)胞的端粒則短得多。在大多數(shù)人類體細(xì)胞內(nèi),端粒隨著細(xì)胞的每一次分裂而不斷縮短,最終導(dǎo)致染色體失去其穩(wěn)定性,細(xì)胞進(jìn)入衰老期。在微生物和腫瘤細(xì)胞內(nèi),存在
[Abstract]:Background Hepatitis C virus hepatitis C virus (HCV) is the main cause of non-A hepatitis B after blood transfusion. Hepatitis C is also a global infectious liver disease. More than 50-85% of patients with acute hepatitis C will develop chronic hepatitis C. If the disease progresses further, it will develop into cirrhosis and hepatocellular carcinoma, according to the Centers for Disease Control and Prevention. Some 20% to 30% patients with chronic hepatitis C will eventually develop fatal clinical symptoms and complications. Experts predict that in the next 10-20 years. Chronic hepatitis C will become one of the major burdens of the health care system as a result of the development of asymptomatic or mild disease patients into end-stage liver disease or even liver cancer. 1989. For the first time, molecular biological techniques have been used to identify the genome of hepatitis C. however, no ideal hepatitis C virus cell model has been established so far. There is a growing awareness of the genetic structure and individual viral proteins of hepatitis C virus, but there is a lack of such a reliable and effective virus culture system. The study of the replication and pathogenesis of hepatitis C virus has been greatly restricted. At the same time. Studies on hepatitis C vaccines and effective treatments have also failed. Hepatitis C virus can infect lymphocyte-derived cells. Human peripheral blood, especially human peripheral blood mononuclear cells But mononuclear cells belong to normal somatic cells and their survival time is limited. If normal PBMC is used to establish the model of hepatitis C virus cells in vitro, the survival time of PBMC must be prolonged. The chromosome of eukaryotic cell determines the genotype of the cell. The terminal structure of chromosome is called telomere. The embryo cell has long chromosome. In most human somatic cells, telomeres are shortened with each cell division, resulting in chromosomes losing their stability. Cells enter the aging phase. They are present in microbes and tumor cells.
【學(xué)位授予單位】：山東大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2005
【分類號(hào)】：R373.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前3條

1 王捍國(guó),肖明振,趙守亮,郝建軍,張進(jìn);永生化人成牙本質(zhì)細(xì)胞樣細(xì)胞系的建立[J];第四軍醫(yī)大學(xué)學(xué)報(bào);2003年10期

2 王新文;人類細(xì)胞永生化的研究進(jìn)展[J];牙體牙髓牙周病學(xué)雜志;2003年04期

3 殷曉雪,陳仲?gòu)?qiáng),郭昭慶,黨耕町,馬慶軍,王申五;轉(zhuǎn)導(dǎo)人端粒酶逆轉(zhuǎn)錄酶基因致人成骨細(xì)胞永生化的研究[J];中華醫(yī)學(xué)雜志;2003年14期

，

本文編號(hào)：1412122